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Epidemiologic and clinical research in osteoarthritis (OA) continues to focus on analytic and descriptive
epidemiology, and the role of both nonpharmacologic and pharmacologic therapies in the management
of OA, respectively. A systematic literature review was conducted using PubMed for the period between
September 1, 2011 and March 31, 2012. Selected articles in these areas are discussed in this narrative
review article.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common form of arthritis, and
is a major cause of morbidity, activity limitation, physical
disability, excess health care utilization and reduced health-
related quality of life, especially in people aged 45 and above1.
OA can be considered as a disease deﬁned by characteristic
structural alterations of the joint, including focal degradation of
articular cartilage and remodeling of subchondral bone with the
formation of osteophytes at the joint margins, as well as an
illness deﬁned by a person’s symptoms, including pain, fatigue,
mood alterations and sleep disturbance2. Symptomatic hip and
knee OA have been shown to be associated with excess all-cause
mortality3,4.
Epidemiologic and clinical research in OA continues to focus on
analytic and descriptive epidemiology, and the role of both non-
pharmacologic and pharmacologic therapies in the management of
OA, respectively. This review highlights selected articles in these
areas published in the peer-reviewed literature during the period
from September 2011 through March 2012. The updated 2012
American College of Rheumatology recommendations for the
management of hand, hip and knee OA were published in April
2012; they are cited here because of relevance to readers but are not
reviewed in detail in this manuscript5.M.C. Hochberg, 10 S. Pine St.,
-6474; Fax: 1-410-706-0231.
du.
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The primary literature search was conducted using PubMed
(http://www.ncbi.nlm.nih.gov/pubmed/) with the search terms
“osteoarthritis [ti] AND clinical [All Fields]” and the following limits
activated: humans, English language, all adult 19þ years, published
between September 1, 2011 and March 31, 2012. This search iden-
tiﬁed 113 articles. A secondary literature search was then con-
ducted with the search terms “osteoarthritis [ti] AND hand”,
“osteoarthritis [ti] AND hip”, and “osteoarthritis [ti] AND knee”,
with the same limits; these searches identiﬁed a total of 40, 71 and
208 articles, respectively.
The titles of all articles were reviewed in order to reﬁne the topic
area; articles in the topic areas of biology, biomarkers, genetics and
genomics, imaging, and rehabilitation and outcomeswere excluded
from further review as they are covered by other authors in this
issue.
Individual articles were selected for discussion in this manu-
script at the sole discretion of the author.Results
Epidemiology
Haugen and colleagues reported on the descriptive epidemi-
ology of hand OA in the Framingham Study6. Hand OA was deﬁned
as one or more joints with KellgreneLawrence (KL) grade 2 or
higher changes. The age-standardized prevalence of hand OA was
only modestly higher in women (44.2%) than men (37.7%), whereasublished by Elsevier Ltd. All rights reserved.
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much higher in women than men (15.9% vs 8.2%) as was that of
erosive OA (9.9% vs 3.3%). The crude incidence of hand OA over 9-
year follow-up was similar in women and men, whereas the vast
majority of both women andmenwith hand OA at baseline showed
progression during follow-up. Development of erosive disease
occurred mainly in those with nonerosive disease at baseline, and
was more frequent in women (17.3%) than men (9.6%). These
ﬁndings further support the observation that erosive OA is part of
the spectrum of hand OA and not a separate entity.
The effect of case deﬁnition of OAwas explored in ameta-analysis
by Pereira and colleagues7. These authors performed a systematic
review of studies of OA incidence and prevalence from 1995 through
2011 and fully analyzed 72 articles that reported descriptive epide-
miology of hand, hip and/or knee OA. Radiographic deﬁnitions were
most commonly used for classiﬁcation with symptomatic and self-
reported status less common in descending order. Based on radio-
graphic criteria, prevalence was highest for hand OA and lowest for
hipOA; however, therewas considerableheterogeneity of prevalence
estimates across studies. Furthermore, while there were no differ-
ences in summary prevalence estimates by gender for hand and hip
OA, there was a signiﬁcantly greater prevalence of radiographic knee
OA amongwomen compared tomen. Similar patterns of results were
noted using other case deﬁnitions; however, overall estimates were
lowest using the self-reported case deﬁnitions at all sites except for
knee OA in men. The authors concluded that method of case deﬁni-
tion needs to be considered when comparing results of descriptive
epidemiologic studies of OA.
Another method of case deﬁnition is the use of hand photo-
graphs. The technique of hand photography for assessing OA was
initially introduced by Acheson and colleagues over 40 years ago in
the New Haven Study of Joint Diseases8 and used by Hirsch and
colleagues in the Women’s Health and Aging Study some 20 years
ago9. Jonsson and colleagues have now demonstrated the reliability
and validity of high quality digital photographs of the hands for the
diagnosis of hand OA in 381 elderly subjects enrolled in the AGES-
Reykjavik Study10.
Temporal trends in knee OA in the United States were examined
using data from several rounds of the National Health and Nutrition
Examination Survey (NHANES) conducted over a 30-year period
and examination cycles of the Framingham Osteoarthritis Study
conducted over a 20-year period11. These authors reported
a signiﬁcant increase in frequency of age-adjusted frequent knee
pain and symptomatic radiographic knee OA that was only partially
explained by changes in body mass index (BMI). While they did not
offer explanations for this increase in knee pain, they did suggest
that it may be related to the increase in the rate of total knee
arthroplasties being performed in the US as well as several Euro-
pean countries.
A systematic review of observational epidemiologic studies
conﬁrmed that knee injury was a major risk factor for the devel-
opment of knee OA and that this result was consistent across study
design, gender, type of knee injury and method of case deﬁnition of
knee OA12. These results support public health recommendations
by the Arthritis Foundation and Centers for Disease Control and
Prevention focusing on primary prevention of knee OA through
reducing the incidence of major knee injuries13.
Treatment
Nonpharmacologic modalities
Weight loss. Weight reduction is recommended for the manage-
ment of patients with symptomatic lower limb OA by all major
rheumatology professional societies5,14e16. Another randomized
controlled trial, conducted over 52-weeks in 96 Danish patientswith symptomatic radiographic knee OA, found that weight loss
accomplished through an intensive low calorie diet was associated
with a signiﬁcant reduction in knee pain, as measured by the
Western Ontario MacMaster Osteoarthritis Index (WOMAC), but
not function, as measured by both the WOMAC and Health
Assessment Questionnaire17. Furthermore, the mean improvement
in knee pain (7.2 units on a 0e100 normalized scale) was less than
the minimal clinically important difference of 10 units and the
proportion of subjects having a substantial (50 percent)
improvement in pain did not differ signiﬁcantly between the
groups. The authors did not assess potential effects of weight loss
on structure modiﬁcation as they did not obtain follow-up knee
radiographs at end of study.
Bariatric surgery is used as part of an overallweightmanagement
strategy in morbidly obese (BMI 35 kg/m2) patients and results in
not only weight loss but also improvement in comorbidities
including type 2 diabetes mellitus and hypertension. Gill and
colleagues reported the results of a systematic review to determine
whetherweight loss following bariatric surgerywas associatedwith
improvement in pain in patients with hip or knee OA18. They iden-
tiﬁed six studies, ﬁve case series and one caseecontrol study; there
wereno randomized controlled trials comparing bariatric surgery to
intensive dietary weight loss strategies. They concluded that,
despite the relative paucity of high quality evidence, the data sup-
ported an association between weight loss following bariatric
surgery and improvement in hip and knee pain.
Pinto and colleagues concluded that there was only limited
evidence for the cost-effectiveness of nonpharmacologic, nonsur-
gical interventions, including weight loss, for the management of
hip and/or knee OA19. These authors stressed the need for high-
quality economic evaluations in order to demonstrate value for
these nonpharmacologic interventions. Such a study of bariatric
surgery should include assessment of not only OA-related
outcomes but also effects of the interventions on comorbidities,
including type 2 diabetes, hypertension and cardiovascular disease,
and the need for concomitant therapies.
Pharmacologic therapies
Complementary and alternative medicine (CAM). Lapane and
colleagues analyzed baseline data from the Osteoarthritis Initiative
and reported that almost one-half of subjects with radiographic
tibiofemoral knee OA reported using one or more types of CAM;
furthermore, nearly one-half of these subjects used CAM in
combination with conventional therapies20. The most common
type of CAM therapy used was nutritional supplements, including
chondroitin sulfate and glucosamine. The study was limited by its
cross-sectional design and no conclusions could be made about the
efﬁcacy or safety of CAM therapy.
Chondroitin sulfate and glucosamine sulfate are registered as
pharmacologic therapies in some countries in Europe and consid-
ered slow-acting, symptomatic drugs for osteoarthritis (SySA-
DOAs); however, despite published recommendations supporting
their use14,16, there remains controversy about their efﬁcacy for
treating OA21. Gabay and colleagues reported results of a 6-month,
randomized, controlled trial of chondroitin sulfate in 162 patients
with symptomatic radiographic hand OA22. Patients allocated to
receive chondroitin sulfate at a dose of 800 mg/day had signiﬁ-
cantly greater improvement in global assessment of hand pain and
self-reported hand function, as measured by the Dreiser index, than
those allocated to receive placebo; there was no evidence of effect
modiﬁcation by presence of erosive OA and no difference is
frequency of reported adverse events.
Nonsteroidal anti-inﬂammatory drugs (NSAIDs). Published recom-
mendations continue to support the use of NSAIDs for the
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suggested that they be used in the lowest dose for the shortest
duration possible in order to minimize the occurrence of adverse
events. Strand and colleagues reported results of a randomized,
double-blind, controlled trial comparing continuous vs intermit-
tent use of celecoxib 200mg/day for the prevention of ‘ﬂares’ in 858
patients with hip or knee OA23. Patients allocated to continuous
celecoxib had an almost 50 percent reduction in the rate of ‘ﬂares’
over the 6-month treatment period; this corresponded to approx-
imately two fewer ‘ﬂares’ over the treatment period. Numerous
secondary outcomes and results of post-hoc analyses supported the
greater efﬁcacy of continuous vs intermittent therapy. Surprisingly,
there were no signiﬁcant differences in adverse events between the
groups.
Topical NSAID therapy is recommended for management of
hand and knee OA, especially in older patients5. Roth and Fuller
reported results of an integrated safety analysis of data from over
1,000 patients with hand or knee OA who were enrolled in seven
randomized controlled trials of topical diclofenac solution for up to
12 weeks24. Dry skin was the most common adverse event in the
topical diclofenac group occurring in one-third of subjects; there
was no difference in blood pressure or laboratory assessments
between the groups.
Intra-articular therapy. There were a plethora of publications over
this period summarizing results of case series, open-label extension
studies and randomized controlled trials of intra-articular hyalur-
onan preparations for OA25e33. As noted by McNeil, the evidence
supporting the efﬁcacy of this treatment modality remains con-
ﬂicting with heterogeneous results of multiple meta-analyses34. I
agree with this conclusion.
Centrally acting agents. Duloxetine, a serotonin norepinephrine
reuptake inhibitor, was approved by the U.S. Food and Drug
Administration for the treatment of chronic pain in patients with
knee OA in 2010. Frakes and colleagues performed a randomized,
double-blind, controlled trial to determine the efﬁcacy and safety of
duloxetine as adjunctive therapy when added to optimally dosed
background NSAIDs in 524 patients with knee OA with persistent
moderate-to-severe knee pain; over three-quarters of patients
were taking either ibuprofen or naproxen, with a minority taking
meloxicam, celecoxib or diclofenac35. Patients allocated to dulox-
etine had signiﬁcantly greater improvement in pain, as measured
by the Brief Pain Inventory and WOMAC, as well as self-reported
function; the OARSI-OMERACT responder criteria was satisﬁed by
almost 70 and 50 percent of duloxetine and placebo-treated
patients. Adverse events were more common, as expected, in the
duloxetine than placebo-treated patients. The results of this study
support the use of duloxetine as adjunctive therapy in knee OA
patients with an inadequate response to oral NSAIDs. It would be of
interest to see a randomized controlled trial comparing duloxetine
and opioid analgesics in this clinical situation.
Biologic agents. Monoclonal antibodies are now being explored as
biologic agents in patients with OA. Tanezumab is a monoclonal
antibody to nerve growth factor that is being developed for treat-
ment of pain in patients with moderate-to-severe hip and knee OA;
the development program was put on temporary hold by the U.S.
Food and Drug Administration in 2010 because of reported serious
adverse events of osteonecrosis. A phase II study of tanezumabwas
conducted in Japanese patients with knee OA; patients allocated to
receive tanezumab at doses of 25, 100 and 200 mg/kg intravenously
reported signiﬁcant improvement in both knee pain and function
compared to patients who received placebo36. No events of osteo-
necrosis were reported in this article.Adalimumab is a monoclonal antibody to tumor necrosis factor
that is used for the treatment of patients with rheumatoid arthritis
and other systemic inﬂammatory conditions. In an investigator-
initiated study, Verbruggen and colleagues examined the struc-
ture modifying effect of adalimumab in 60 patients with erosive
hand OA37. There were no signiﬁcant differences between treat-
ment groups in either the number of subjects who developed new
erosive interphalangeal joints or the number of new erosive
interphalangeal joints. There also were no signiﬁcant differences
between groups in symptoms, as measured by the Australian
Canadian Osteoarthritis (AUSCAN) Index, or grip strength. In
exploratory post-hoc analyses, however, the authors did ﬁnd
a signiﬁcant beneﬁt to adalimumab therapy in subjects who had
interphalangeal joints with soft tissue swelling and/or palpable
effusion. Adverse events were more common in the adalimumab-
treated patients, as expected.
Emerging agents. Matthews and Hunter published a comprehen-
sive review of pharmacologic agents in phase II and III development
for both symptomatic and structural outcomes in patients with OA
that is recommended to the reader38.
Conclusion
There continues to be publication of many clinical studies in OA.
In addition to the articles highlighted above, the reader is referred
to the proceedings of an Osteoarthritis Summit and State of the
Science held at the Hospital for Special Surgery in June and July
2011, respectively39,40.
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